Advertisement
Advertisement
U.S. markets close in 4 hours 50 minutes
Advertisement
Advertisement
Advertisement
Advertisement

NeuBase Therapeutics, Inc. (NBSE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2500+0.0055 (+2.25%)
As of 11:08AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.2445
Open0.2427
Bid0.2400 x 1100
Ask0.2570 x 1800
Day's Range0.2400 - 0.2596
52 Week Range0.1720 - 2.0800
Volume27,830
Avg. Volume278,415
Market Cap8.309M
Beta (5Y Monthly)0.92
PE Ratio (TTM)N/A
EPS (TTM)-1.0440
Earnings DateFeb 08, 2023 - Feb 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NBSE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NeuBase Therapeutics, Inc.
    Analyst Report: Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more
  • American City Business Journals

    NeuBase Therapeutics selling stake in company to New York investment firm Alumni Capital

    NeuBase specializes in genetic medicine therapies that target disease-triggering DNA and RNA mutations.

  • GlobeNewswire

    NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022

    PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2022, and other recent developments. “Fiscal year 2022 was a challenging period in our Company’s history as we faced a tightening of the broader capital markets for

  • GlobeNewswire

    NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company

    PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced a research agreement with a Top 10 Global Healthcare company (“Healthcare Company”) (based on 2021 revenues). For this research, the Healthcare Company will evaluate NeuBase’s PATrOL™ technology for three monogenic genetic di

Advertisement
Advertisement